Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Biomarkers in Infection

14. januar 2020 oppdatert av: Nathan Shapiro, Beth Israel Deaconess Medical Center

Early Detection of Inflammatory Biomarkers in Infection

The purpose of this investigation is to evaluate how early biomarkers of infection and inflammation perform in identifying patients at risk for poor outcome in sepsis and septic shock.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

The body's immune system and a subsequent inflammatory response are triggered during infection. The detection of an activated immune system, and an indication of the degree of the host response, is helpful to the clinician both in assessing the severity of infection and in patient treatment and management. Currently, the white blood cell count and the differential are the most common laboratory parameters for measuring host response. The sedimentation rate and CRP are also used to detect inflammation. However, these tests are all imperfect predictors, and a test providing a better assessment of immune response would be helpful to the clinician in patient care. Additionally, understanding host response to infection may be helpful in understanding the biology and pathophysiology of sepsis. There are other biomarkers and inflammatory markers that may be found early in the initial presentation of infection such as cytokines (VEGF IL-1,IL-4,IL-6, IL-10, PAF, TNF, lectins iNoS,etc.) and clotting factors (protein C, d-dimer, complements involved in the clotting cascade, CRP, etc) that may provide a means of early detection of systemic inflammation, cell dysfunction, and related conditions. Early identification of patients at risk for systemic inflammatory syndromes, sepsis and septic shock may help direct patients to earlier antibiotic administration and early intervention with goal directed therapy. It may also serve as a tool for risk stratification when components such as age, comorbid illness and infection type are included.

The endothelium and endothelial cell markers are important in sepsis, yet a somewhat under-studied field of research. Additionally, the endothelium is a key regulator of the microcirculation, a place where oxygen diffusion occurs. One focus of this study is to measure endothelial markers (ie VEGF) and other cytokines with the goal of correlating these markers with severity of sepsis. Another focus is to study the response of various components in the blood, including the leukocytes, red cells, the endothelium, as well as cellular components such as the mitochondria. We will specifically look at alterations in thiamine, Vitamin D, CoQ10,l-carnitine and other nutrients as part of (and as related to) the body's response. Recently, a non-invasive method of assessing microvascular circulation by orthogonal polarization spectral (OPS) imagery has become available using a non-invasive technology known as orthogonal polarization spectroscopy. This technique enables direct visualization and quantification of microcirculatory blood flow, and represents an important surrogate outcome to which endothelial cell marker may be correlated. This will involve placing the microscopy probe gently against the sublingual mucosa and collecting a videotape of the circulation lasting about twenty seconds. This process involves minimal (or no) risk - it is akin to taking a temperature and uses no radiation. This videotape will be examined later by a novel software program that quantifies the circulation and used as an important surrogate outcome measure. Additionally, we are going to perform echocardiography to better understand the heart's response to sepsis, and correlated the molecular responses that we find with the changes in the responses by the heart.

This is a multicenter, observational pilot study which aims to evaluate how early biomarkers of infection an inflammation perform in identifying patients at risk for poor outcomes in sepsis and septic shock. The study will utilize a cohort of patients presenting to the ED with suspected infection as well as non-infected control population.

These patients will be compared with a non-infected population.

Enrolled subjects in the infected group will have blood samples and chart review obtained at enrollment, 24, 48 and 72 hours. For the control group, only a single blood draw will be collected at enrollment.

Enrolled subjects will also undergo physiologic assessments using echocardiography, Microscan, Non-invasive cardiac output monitor (NICOM), extremity temperature as well as End-Tidal C02 measurements if a trained researcher is present.

Studietype

Observasjonsmessig

Registrering (Forventet)

4200

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Beth Israel Deaconess Medical Center
        • Ta kontakt med:
      • Boston, Massachusetts, Forente stater, 02114
        • Aktiv, ikke rekrutterende
        • Massachusetts General Hospital
      • Boston, Massachusetts, Forente stater, 02215
        • Aktiv, ikke rekrutterende
        • Brigham and Women's Hospital
      • Worcester, Massachusetts, Forente stater, 01608
    • New York
      • Brooklyn, New York, Forente stater, 11215
        • Rekruttering
        • New York Methodist Hospital
        • Ta kontakt med:
          • Robert Birkhahn, MD
        • Hovedetterforsker:
          • Rorber Birkhahn, MD
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37232
        • Rekruttering
        • Vanderbiltt University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Wesley Self, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients presenting to the Emergency Department with suspected infection as well as a non-infected control population.

Beskrivelse

Inclusion Criteria for Infected subjects:

  • Age 18 years of age or older
  • Confirmed or suspected infection

Inclusion Criteria for Control Subjects:

  • Age 18 years of age or older
  • A non-infectious clinical presentation to include
  • Normal white blood cell count ( > 4,000 and/or < 12,000)
  • Normothermia ( > 96.5 and/or less 100.4)
  • Absence of the following clinical complaints: productive cough, fever, pyuria, rash
  • No evidence of acute coronary syndrome

Exclusion Criteria for Control Subjects:

- Suspected infection

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Infected Group
subjects with suspected infection
Non-infected group
subjects without any infection

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
28 day in-hospital mortality
Tidsramme: within 28 days after inclusion
participants will be followed up for 28 days
within 28 days after inclusion

Sekundære resultatmål

Resultatmål
Tidsramme
Organ Dysfunction assessed by Sepsis-related Organ Failure Assessment (SOFA) Score
Tidsramme: within 24 hours
within 24 hours

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Nathan Shapiro, MD MPH, Beth Israel Deaconess Medical Center

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. april 2006

Primær fullføring (Forventet)

1. april 2023

Studiet fullført (Forventet)

1. april 2023

Datoer for studieregistrering

Først innsendt

8. september 2015

Først innsendt som oppfylte QC-kriteriene

8. september 2015

Først lagt ut (Anslag)

10. september 2015

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. januar 2020

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. januar 2020

Sist bekreftet

1. januar 2020

Mer informasjon

Begreper knyttet til denne studien

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Sepsis

3
Abonnere